Become A Wiser, More Profitable Investor

✅   Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimers disease

Health

Objectives To assess the cost-effectiveness of aducanumab at its updated price for treating patients with mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD). Design Cost-effectiveness analysis. Settings A five-state Markov model was constructed using 10 000 virtual patients to assess the cost-effectiveness of aducanumab from the perspective of the US healthcare system. The model employed a one-year cycle time and a lifetime time horizon. Transition probabilities and mortality rates were derived from a literature review. To address uncertainty and generalise the base case results, both one-way and probabilistic sensitivity analyses were conducted. Participants 10 000 virtual patients with MCI and mild AD.

BMJ     Apr 28, 2025